TING-HSING CHAO2026-10-162026-10-162018-08-01Pure ID: 15264131Pure UUID: 824b0974-ad94-480d-af22-3fc0c6e3875f10.1016/j.jfma.2018.07.007https://www.scopus.com/pages/publications/85050115418https://scholars.csmu.edu.tw/handle/123456789/25729In the page 225, left column, lines 3–7 of the article cited above, the sentence “The European Medicines Agency has approved alirocumab and evolocumab for patients who fail to achieve acceptable lipid control despite optimal statin therapy, patients with homozygous FH (HoFH), and statin-intolerant patients”, should have read “The European Medicines Agency has approved alirocumab and evolocumab for patients who fail to achieve acceptable lipid control despite optimal statin therapy, patients with homozygous FH (HoFH; evolocumab only), heterozygous FH, and statin-intolerant patients.” The authors would like to apologize for any inconvenience caused.2enjournal article